{"success":true,"count":1,"items":[{"videoId":"BfttEe910n8","chunkIndex":0,"totalChunks":1,"title":"10 ASCO 2026 Breakthroughs You Need to Know","thumbnail":"https://i.ytimg.com/vi/BfttEe910n8/maxresdefault.jpg","duration":451,"uploader":"StemImmune LLC","youtubeUrl":"https://www.youtube.com/watch?v=BfttEe910n8","keywords":["oncology","cancer-immunotherapy","precision-medicine","biotech","adc","car-t","bispecific-antibodies","liquid-biopsy","cancer-vaccines","drug-development"],"normalizedKeywords":["기술 트렌드","헬스·웰빙","비즈니스·전략"],"targetAudience":[{"who":"암 연구자","why":"최신 면역치료·정밀의학 트렌드와 임상 방향을 한 번에 파악할 수 있음"},{"who":"바이오텍 실무자","why":"ADC, 이중항체, CAR-T, 백신 등 파이프라인 기회를 읽는 데 유용함"},{"who":"투자자","why":"향후 5년 유망한 종양학 섹터와 기술 성숙도를 가늠할 수 있음"},{"who":"의료진","why":"과잉치료 회피, liquid biopsy, 병용요법의 임상 적용 흐름을 이해하기 좋음"}],"normalizedAudience":["리서처·학자","투자자·VC"],"summary":"이 영상은 ASCO 2026에서 부상한 10대 종양학 트렌드를 통해 암 치료의 미래가 어디로 가는지 정리한다. 핵심 메시지는 정밀진단과 차세대 면역치료를 결합해, 더 개인화되고 더 오래 지속되는 항종양 반응을 만드는 방향으로 산업이 이동하고 있다는 점이다.\n\n내용은 암 백신의 재부상, solid tumor로 확장되는 CAR-T, 급성장 중인 bispecific antibody, ADC의 병용요법 시대, liquid biopsy의 표준화, 그리고 pancreatic cancer에서의 새로운 가능성까지 폭넓게 다룬다. 또한 미래의 유망 분야를 tier별로 정리하며, 단일 약물보다 병용 플랫폼과 미세환경 조절이 앞으로의 경쟁축이 될 것이라고 강조한다.","insights":["암 치료의 중심은 단일약물이 아니라 병용 플랫폼으로 이동한다.","정밀진단은 치료 선택뿐 아니라 불필요한 치료를 줄이는 도구다.","면역치료의 다음 단계는 종양세포보다 미세환경을 바꾸는 것이다.","유망 파이프라인은 ADC·이중항체·백신처럼 확장성과 조합성이 크다.","Liquid biopsy는 연구용 기술에서 일상 진료의 의사결정 도구로 간다."],"keyClips":[{"clipId":"BfttEe910n8:c0:3-9","startSegmentIndex":3,"endSegmentIndex":9,"startTime":12.23,"endTime":61.04,"durationSeconds":48.8,"preview":"ASCO 2026 큰그림","mustSee":true},{"clipId":"BfttEe910n8:c0:10-16","startSegmentIndex":10,"endSegmentIndex":16,"startTime":61.04,"endTime":106.56,"durationSeconds":45.5,"preview":"암 백신의 재부상","mustSee":true},{"clipId":"BfttEe910n8:c0:17-24","startSegmentIndex":17,"endSegmentIndex":24,"startTime":106.56,"endTime":170.68,"durationSeconds":64.1,"preview":"CAR-T와 이중항체","mustSee":false},{"clipId":"BfttEe910n8:c0:25-30","startSegmentIndex":25,"endSegmentIndex":30,"startTime":170.68,"endTime":209.76,"durationSeconds":39.1,"preview":"ADC 병용시대","mustSee":true},{"clipId":"BfttEe910n8:c0:31-40","startSegmentIndex":31,"endSegmentIndex":40,"startTime":209.76,"endTime":277.52,"durationSeconds":67.8,"preview":"과잉치료를 줄이다","mustSee":true},{"clipId":"BfttEe910n8:c0:41-44","startSegmentIndex":41,"endSegmentIndex":44,"startTime":277.52,"endTime":304.36,"durationSeconds":26.8,"preview":"췌장암 새 희망","mustSee":false},{"clipId":"BfttEe910n8:c0:45-65","startSegmentIndex":45,"endSegmentIndex":65,"startTime":304.36,"endTime":451.6,"durationSeconds":147.2,"preview":"향후 5년 로드맵","mustSee":true}],"curatedSegments":[{"segmentIndex":6,"text":"[music] The future of cancer treatment lies in combining precision diagnostics with next-generation [music] immunotherapies to create highly personalized and durable anti-tumor [music] responses.","startTime":34,"endTime":35.12,"durationSeconds":1,"level":"C1","overallScore":8,"rationale":"미래 방향을 원리로 압축 제시."},{"segmentIndex":16,"text":"Why it matters: cancer vaccines may become an important strategy for eliminating minimal residual disease MRD [music] and preventing recurrence by establishing long-term immune memory.","startTime":95.84,"endTime":106.56,"durationSeconds":11,"level":"C1","overallScore":8,"rationale":"의미와 활용 가치를 명확히 설명."},{"segmentIndex":27,"text":"The discussion has shifted [music] from do ADCs work to how can ADCs work even better?","startTime":179.84,"endTime":185.92,"durationSeconds":6,"level":"B2","overallScore":8,"rationale":"논의의 단계 변화가 선명한 통찰."},{"segmentIndex":53,"text":"Future therapies will increasingly focus on transforming the tumor microenvironment into a more immune-permissive state.","startTime":351.72,"endTime":358.6,"durationSeconds":7,"level":"C1","overallScore":7.8,"rationale":"치료 방향의 원칙을 제시함."},{"segmentIndex":57,"text":"The era of single-agent oncology is gradually giving way to integrated treatment platforms.","startTime":383.88,"endTime":389,"durationSeconds":5,"level":"C1","overallScore":8,"rationale":"시대 전환을 선명히 표현한 문장."},{"segmentIndex":64,"text":"The convergence of precision diagnostics, [music] advanced biologics, engineered immune cells, and innovative vaccine technologies is creating unprecedented opportunities to improve patient outcomes.","startTime":429.76,"endTime":441.6,"durationSeconds":12,"level":"C1","overallScore":7.6,"rationale":"기술 융합의 의미와 효과를 통찰 있게 설명."},{"segmentIndex":7,"text":"The future of cancer treatment is personalized, immune-driven, [music] and increasingly combination-based.","startTime":35.12,"endTime":46.08,"durationSeconds":11,"level":"B2","overallScore":6.8,"rationale":"핵심 흐름을 간결히 일반화함."},{"segmentIndex":20,"text":"New designs improve tumor infiltration and persistence while countering immunosuppressive tumor microenvironments, moving beyond hematologic disease towards solid tumor impact.","startTime":122.56,"endTime":136.76,"durationSeconds":14,"level":"C1","overallScore":7,"rationale":"기술 발전의 의미를 방향성 있게 설명."},{"segmentIndex":24,"text":"Many experts [music] now believe bispecific antibodies will become a major pillar of cancer immunotherapy.","startTime":165.32,"endTime":170.68,"durationSeconds":5,"level":"B2","overallScore":6.8,"rationale":"전문가 관점의 강한 전망 제시."},{"segmentIndex":30,"text":"ADCs are rapidly [music] becoming foundational components of modern oncology treatment regimens.","startTime":204.44,"endTime":209.76,"durationSeconds":5,"level":"B2","overallScore":6.8,"rationale":"위상 변화를 일반화해 전달함."},{"segmentIndex":32,"text":"One of the most practice-changing studies presented at ASCO 2026 [music] demonstrated that genomic testing can identify patients who may safely avoid chemotherapy.","startTime":214.44,"endTime":224.36,"durationSeconds":10,"level":"C1","overallScore":7,"rationale":"실제 치료 변화 가능성을 보여줌."},{"segmentIndex":35,"text":"It is increasingly about identifying patients who do not require unnecessary treatment.","startTime":238.16,"endTime":242.96,"durationSeconds":5,"level":"B2","overallScore":6.8,"rationale":"정밀의학의 새 역할을 선명히 설명."},{"segmentIndex":40,"text":"Liquid biopsy is rapidly moving from research [music] settings into routine clinical practice.","startTime":272.2,"endTime":277.52,"durationSeconds":5,"level":"B2","overallScore":7,"rationale":"현장 도입 전환을 잘 보여줌."},{"segmentIndex":44,"text":"These advances [music] suggest that pancreatic cancer may finally be entering a new therapeutic era.","startTime":298.96,"endTime":304.36,"durationSeconds":5,"level":"B2","overallScore":6.8,"rationale":"변화의 전환점을 해석해 제시함."},{"segmentIndex":48,"text":"These agents are designed to block multiple tumor pathways, recruit immune cells, remodel the tumor microenvironment.","startTime":321.44,"endTime":328.56,"durationSeconds":7,"level":"C1","overallScore":7,"rationale":"기능과 목적이 명확한 설명 문장."},{"segmentIndex":51,"text":"Cancer is [music] no longer viewed solely as a disease of malignant cells.","startTime":336.08,"endTime":340.24,"durationSeconds":4,"level":"C1","overallScore":7,"rationale":"질병 관점 전환을 드러내는 문장."},{"segmentIndex":55,"text":"Perhaps the strongest theme throughout ASCO 2026 was the growing importance of [music] combination approaches.","startTime":363.08,"endTime":369.16,"durationSeconds":6,"level":"C1","overallScore":6.8,"rationale":"행사 핵심 흐름을 압축해 전달."},{"segmentIndex":63,"text":"ASCO [music] 2026 reinforced a fundamental shift in oncology.","startTime":418.88,"endTime":429.76,"durationSeconds":11,"level":"C1","overallScore":6.4,"rationale":"종양학 변화의 핵심 방향을 압축 제시."},{"segmentIndex":65,"text":"For researchers, [music] clinicians, investors, and biotechnology companies, ASCO 2026 [music] provides a clear road map for where cancer innovation is heading next.","startTime":441.6,"endTime":451.6,"durationSeconds":10,"level":"C1","overallScore":6.8,"rationale":"이해관계자별 시사점과 미래 방향을 제시."}],"generatedAt":"2026-06-25T00:28:01.350Z","keyClipsTotalSec":348}]}